Navigation Links
LeMaitre Vascular to Participate in 28th Annual Cowen and Company Health Care Conference
Date:3/11/2008

BURLINGTON, Mass., March 11 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), which develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease, is scheduled to participate in the 28th Annual Cowen and Company Health Care Conference on Tuesday, March 18, 2008, in Boston.

George W. LeMaitre, Chairman and Chief Executive Officer, and David B. Roberts, President, will provide an update on the company at 10:15 am Eastern Time.

A live audio webcast of the presentation will be available via the Internet at http://ir.lemaitre.com and will be available for replay for approximately three months.

About LeMaitre Vascular

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease. The Company's principal executive offices are located at 63 Second Avenue, Burlington, Massachusetts 01803. Additional information can be found at http://www.lemaitre.com.


'/>"/>
SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
2. LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors
3. BioVascular, Inc. Expands Executive Team
4. HealthAware Introduces Its VascularAware Cardiovascular Disease Module
5. Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System
6. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
7. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
8. The Wisconsin Heart Hospital Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery
9. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
10. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
11. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2008)...FirstCall/ -- Eli Lilly and,Company (NYSE: LLY ) ...ion,of SGX Pharmaceuticals, Inc. (Nasdaq: SGXP ),...n drug discovery and development in the area,of on...s Special,Stockholders Meeting, in which a majorit... agreement with Lilly. Under the agreement, Lilly ...
(Date:8/20/2008)... and Caregivers, Grassroots ...ewswire-USNewswire/ -- Inc. Magazine has,named Sen...an for,low-income seniors, the number one fastest-...rt of Inc.,s annual list of the country,s 500 fast...1,000 percent from 2004 to 2007., "This is a rewa...
(Date:8/20/2008)...ll/ -- CEL-SCI CORPORATION,(Amex: CVM ) reports f...ing,June 30, 2008., The Company,s loss from opera...76,679 versus a loss of $3,776,263 during the same...ns for the nine months ended June 30, 2008,was $7,...e nine months in,2007., The net loss per common s...
(Date:8/20/2008).../ -- Huifeng Bio-Pharmaceutical,Technology, Inc (O...producer of plant extracts and pharmaceutical raw ... and food production, today announced it will,be i... August 19-21 in Rio,de Janeiro, Brazil., "Unpara...volved in the,pharmaceutical raw materials industr...
Breaking Biology Technology:Lilly Announces Completion of SGX Acquisition 2Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US 2Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US 3CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 2CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 3CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 4CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 5Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil 2
... During many experiments in molecular biology, t...a cell is examined in order to investigate the rea...uch as viral infections or medical treatment. , ...horoughly, it is converted , to cDNA. If ..., the result , is referred to as a "cDNA ...
... , Guy Adami, Department of Oral Medicin...SA , Vincent Prezioso, Eppendorf Scientif... Introduction , , Transgenic ... incorporated , into their genome. The mo..., into the mouse genome is by microinjectio...
..., George Halley and Vincent Prezioso, PhD ,...lder, CO, USA , Vincent Prezioso, Brinkmann... , NY , , Abstract , ...ular because of their convenience , and t...Typical Hot Start , enzymes utilize chemi...
... Multiporator / Electroporator 2510 , , ... Transformation Protocol , P... , , , , , , , ,... Ustilago maydis fbd11, protoplasts, ... Phytopathogenic fungus, yeast-like growing spo...
Other Biology Technology:Normalizing cDNA libraries using the EppendorfThermomixer 2Normalizing cDNA libraries using the EppendorfThermomixer 3Normalizing cDNA libraries using the EppendorfThermomixer 4The use of TaqMaster PCR Enhancer 2The use of TaqMaster PCR Enhancer 3The use of TaqMaster PCR Enhancer 4The use of TaqMaster PCR Enhancer 5HotMasterAn innovative Hot Start/Cold Stop technology for better , PCR* results 2HotMasterAn innovative Hot Start/Cold Stop technology for better , PCR* results 3HotMasterAn innovative Hot Start/Cold Stop technology for better , PCR* results 4HotMasterAn innovative Hot Start/Cold Stop technology for better , PCR* results 5HotMasterAn innovative Hot Start/Cold Stop technology for better , PCR* results 6HotMasterAn innovative Hot Start/Cold Stop technology for better , PCR* results 7Ustilago maydis 2Ustilago maydis 3
(Date:8/20/2008)...mers called polyketals and their derivatives may i...s acute lung injury, acute liver failure and infla...s and snips of ribonucleic acid to disease locatio...we developed are simply a vehicle to get the drugs...s possible," said Niren Murthy, assistant professo...
(Date:8/20/2008)...ue of the Journal of Lipid Research suggests an ... rising rate of diabetes, especially in children a...he primary mechanism of inheritance; kids get half...scientists are just starting to understand additio...g, which occurs when an insult during a critical p...
(Date:8/19/2008)...lahoma researchers began studying the environmenta...ued the energy industry for decades, they did not ...rganisms capable of converting hydrocarbons into n...oundbreaking processknown as anaerobic hydrocarbon...oduction from older, more mature oil reservoirs li...
(Date:8/19/2008)...versity has received a $3.2 million grant from the...ering, physical science and mathematical disciplin...ellowships, the program can equip experts in field...l modeling and biomaterials to move stem-cell brea...commercially viable therapies. , NSF awarded the...
Breaking Biology News(10 mins):Biodegradable polymers show promise for improving treatment of acute inflammatory diseases 2Biodegradable polymers show promise for improving treatment of acute inflammatory diseases 3OU researchers isolate microorganisms that convert hydrocarbons to natural gas 2OU researchers isolate microorganisms that convert hydrocarbons to natural gas 3$3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells 2$3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells 3Seeing our spouses more negatively might be a positive 11022 1Seeing our spouses more negatively might be a positive 11022 2West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference 11019 1West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference 11019 2AST to Address New Concept in Organ Allocation at March 13 16 Winter Symposium 11014 1AST to Address New Concept in Organ Allocation at March 13 16 Winter Symposium 11014 2Picture This 3A Heart Health Risk Assessment Gets Easier 11012 1Picture This 3A Heart Health Risk Assessment Gets Easier 11012 2Picture This 3A Heart Health Risk Assessment Gets Easier 11012 3
...Max Planck researchers sequence the genome of a mi...ingle-celled organisms, are particularly interesti...der extreme environmental conditions, for instance...r high temperatures. Nature,s masters of adaptatio... can draw conclusions about the first organisms on...
...A new study suggests that restoring a gene often s...struct. The findings could lead to a new strategy ...on a gene known as WWOX, which is lost or silenced...rs of the breast, ovary, prostate, bladder, esopha...t The Ohio State University Comprehensive Cancer C...
...Human activities are degrading the Amazonian fores... a new study that adds the effects of logging to t... 21 October issue of the journal Science , publis...l now, satellite-based methods for measuring defor... of detecting clear-cut swaths of land, where all ...
...The survival rate of HIV-infected patients in Indi...rice of antiretroviral therapy (ART), according to...tious Diseases, now available online. The introduc...ged people to seek HIV treatment because of the ch... than 5 million HIV-infected people living in Indi...
Other Biology News:Life in deadly conditions 2Life in deadly conditions 3Restoring silenced suppressor gene kills lung-cancer cells 2Logging doubles threat to the Amazon, rivaling clear-cutting, study suggests 2HIV mortality in India drops with introduction of generic antiretroviral therapy 2
ANXA11 Immunogen: ANXA11 (NP_001148, 406 a.a. ~ 506 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C
Rabbit polyclonal to MKK6 (phospho S207) ( Abpromise for all tested applications). Antigen: Synthetic phosphopeptide derived from human MKK6 around the phosphorylation site of Serine 207 (V-D-S
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications).
Biology Products: